BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15921390)

  • 1. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
    Kainz B; Fonatsch C; Schwarzinger I; Sperr WR; Jäger U; Gaiger A
    Haematologica; 2005 May; 90(5):695-6. PubMed ID: 15921390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of MLL-AF9 detection in patients with t(9;11)(p22;q23)-positive acute myeloid leukemia.
    Scholl C; Schlenk RF; Eiwen K; Döhner H; Fröhling S; Döhner K;
    Haematologica; 2005 Dec; 90(12):1626-34. PubMed ID: 16330435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detailed analysis of FLT3 expression levels in acute myeloid leukemia.
    Kuchenbauer F; Kern W; Schoch C; Kohlmann A; Hiddemann W; Haferlach T; Schnittger S
    Haematologica; 2005 Dec; 90(12):1617-25. PubMed ID: 16330434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P-glycoprotein expression and prognostic value in acute myeloid leukemia.
    Senent L; Jarque I; Martín G; Sempere A; González-García Y; Gomis F; Pérez-Sirvent M; De La Rubia J; Sanz MA
    Haematologica; 1998 Sep; 83(9):783-7. PubMed ID: 9825574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation.
    Yoshimoto G; Nagafuji K; Miyamoto T; Kinukawa N; Takase K; Eto T; Kato K; Hayashi S; Kamimura T; Ohno Y; Taniguchi S; Harada M
    Bone Marrow Transplant; 2005 Dec; 36(11):977-83. PubMed ID: 16184177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
    Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
    Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype.
    Palmieri S; Ferrara F; Leoni F; Ciolli S; Pollio F; D'Amico MR; Celentano M; Viola A; Vicari L; Izzo B; Pane F
    Hematol Oncol; 2007 Mar; 25(1):1-5. PubMed ID: 17036374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia.
    Buccisano F; Maurillo L; Del Poeta G; Gattei V; Amadori S; Venditti A
    Haematologica; 2006 Dec; 91(12 Suppl):ELT14; author reply ELT15. PubMed ID: 17194674
    [No Abstract]   [Full Text] [Related]  

  • 10. Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway.
    Koh Y; Park J; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Soon Lee D; Yiul Lee Y; Park S; Kim BK
    Ann Hematol; 2009 Nov; 88(11):1089-97. PubMed ID: 19296110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BAALC expression and FLT3 internal tandem duplication mutations in acute myeloid leukemia patients with normal cytogenetics: prognostic implications.
    Baldus CD; Thiede C; Soucek S; Bloomfield CD; Thiel E; Ehninger G
    J Clin Oncol; 2006 Feb; 24(5):790-7. PubMed ID: 16418499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
    Tomizawa D; Tabuchi K; Kinoshita A; Hanada R; Kigasawa H; Tsukimoto I; Tsuchida M;
    Pediatr Blood Cancer; 2007 Aug; 49(2):127-32. PubMed ID: 16807916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLT3 and acute myeloid leukemia: what is the wild type receptor up to?
    Levis M
    Haematologica; 2005 Dec; 90(12):1586. PubMed ID: 16330422
    [No Abstract]   [Full Text] [Related]  

  • 14. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Del Principe MI; Del Poeta G; Spagnoli A; Panetta P; Ammatuna E; Neri B; Ottaviani L; Sarlo C; Venditti D; Quaresima M; Cerretti R; Rizzo M; de Fabritiis P; Lo Coco F; Arcese W; Amadori S; Venditti A
    J Clin Oncol; 2008 Oct; 26(30):4944-51. PubMed ID: 18606980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML).
    Weinstein H; Ravindranath Y; Krischer J; Steuber P; Civin C; Gresik M; Vietti T
    Leukemia; 1992; 6 Suppl 2():52-4. PubMed ID: 1578941
    [No Abstract]   [Full Text] [Related]  

  • 16. New agents in the treatment of acute myeloid leukemia.
    Wiernik PH
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):95-8. PubMed ID: 1780763
    [No Abstract]   [Full Text] [Related]  

  • 17. Multivariate analyses of prognostic factors in acute myeloid leukemia: relevance of cytogenetic abnormalities and CD34 expression.
    Junghanss C; Waak M; Knopp A; Kleine HD; Kundt G; Leithäuser M; Hilgendorf I; Wolff D; Casper J; Freund M
    Neoplasma; 2005; 52(5):402-10. PubMed ID: 16151585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leukemic dermal infiltrate at the exit site of a central venous catheter.
    Martino R; Sureda A; Sitjas D; Nomdedéu J; Domingo-Albòs A
    Haematologica; 1993; 78(2):132-4. PubMed ID: 8349191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
    Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
    Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double intensive consolidation chemotherapy in adult acute myeloid leukemia.
    Harousseau JL; Milpied N; Briere J; Desablens B; Leprise PY; Ifrah N; Gandhour B; Casassus P
    Semin Hematol; 1991 Jul; 28(3 Suppl 4):80-3. PubMed ID: 1780758
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.